Gonadorelin

Gonadorelin reproduces GnRH, the hypothalamic hormone composed of 10 amino acids. FDA-approved diagnostic applications assess pituitary and gonadal function and hypogonadotropic hypogonadism. Use alongside testosterone replacement therapy aims to preserve fertility, testicular size and internal testosterone production by limiting suppression of the HPG axis. Compounded preparations are available by prescription.

• Hormonal Regulation

  Most effective

  Direct endocrine activity produces effects on hormone regulation that are well characterized.

• Reproductive Health

  Effective

  Fertility investigations and reproductive medicine are areas of research and clinical application.

• Metabolic Support

  Moderate

  Hormonal signaling may produce secondary effects on metabolic function.

• Medications

  Caution

  Consult your prescriber before combining this compound with any medication.

• BPC-157

  Compatible

• NAD+

  Compatible

• Vitamin D

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

Week 1–2

Early effects may accompany an adjustment period. Watch for any unwanted reaction as you adapt.

Week 2–4

The principal effects may begin emerging. Follow your clinician’s recommendations for any change in dose.

Week 4–8

Main effects are expected to be apparent at this stage. Review your progress together with your clinician.

Week 8+

Review the outcome with your clinician and decide whether to continue, take a cycle break or adjust the dose. These timings do not establish effectiveness for every compound.

• Bruising, redness or mild soreness where the injection is given
• Possible allergic response; stop use if you develop hives or a rash
• Variable individual response; begin with the lowest dose and watch closely for reactions
• Discuss use with your clinician beforehand and report symptoms that are unusual for you

Gonadorelin: approved in the US.

• US

  Approved

  FDA — approved diagnostic uses assess hypogonadotropic hypogonadism and pituitary-gonadal function; prescription compounding is available.

  Rx required

  Yes

  503A

  Allowed

  Telehealth

  Available

1. Gonadotropin-releasing hormone agonists and antagonists in assisted reproduction (2016)

2. Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis. (2026)

   PMID 41818388DOI 10.1126/science.aeb6999

3. How to pause fertility. (2024)

   PMID 38591514DOI 10.7554/eLife.97432